Score Overview
iMedSync
iAI-powered medication adherence platform that reduces hospital readmissions by 40% through real-time patient monitoring and predictive interventions.
- Strong clinical validation with 3 hospital system pilots showing 40% readmission reduction
- Experienced founding team with combined 25+ years in health tech and clinical operations
- Clear regulatory pathway — FDA Class II 510(k) submission planned for Q3 2026
- $1.2M ARR with 180% net revenue retention, growing 15% MoM
Top Priority
iYour biggest vulnerability is the competitive analysis. A well-informed VC will immediately ask about Epic and Cerner building adherence modules into their EHR platforms. Address this head-on with a "Why Point Solution Wins" argument — speed of innovation, clinical specialization, and integration flexibility that platform vendors can't match.
Competitive Landscape: 52/100
Competitive slide is the weakest — 2x2 matrix positions MedSync favorably but feels cherry-picked.
Target: 75+ / 100
Address the EHR platform risk head — on — explain why point solution wins
Critical Red Flags
iAction Plan
i- 1
Rebuild competitive proof
Slides 9medium effortActionReplace the current 2x2 with a 3-vector competitive framework covering point solutions, EHR platforms, and generalist AI.
Why it mattersThis is the first diligence objection: investors need to see why incumbents cannot absorb the product.
DeliverableOne competitive slide with named competitors, defensibility vectors, and a crisp "why we win" row.
Expected impactTurns competition from a red flag into a focused diligence discussion.
- 2
Ground market sizing
Slides 7low effortActionReplace top-down TAM bubbles with bottom-up math: target hospitals, expected ACV, penetration rate, and beachhead segment.
Why it mattersSeries A investors will discount broad market claims unless the initial wedge is quantified.
DeliverableA market slide with beachhead definition and 3-line TAM/SAM/SOM calculation.
Expected impactImproves market credibility and makes the go-to-market plan easier to underwrite.
- 3
Add unit economics
Slides 11medium effortActionAdd an LTV/CAC and margin table tied to actual hospital pilots or closest available cohort data.
Why it mattersThe financial model currently asks investors to trust the hockey stick without the engine beneath it.
DeliverableOne unit-economics slide with CAC, payback, gross margin, expansion assumptions, and sensitivity notes.
Expected impactReduces financing-risk and scale-risk objections.
- 4
Show product evidence
Slides 4low effortActionAdd real screenshots or a demo-frame sequence that shows the care team workflow end to end.
Why it mattersThe solution is conceptually clear, but investors need to see the product is more than architecture.
DeliverableTwo product screenshots plus one before/after workflow callout.
Expected impactRaises product credibility and reduces "is this built?" pushback.
- 5
Tighten funded milestones
Slides 12low effortActionMap the $12M ask to three concrete milestones and close with a sharper vision statement.
Why it mattersThe ask is clear, but the use of funds needs to feel like a de-risking plan.
DeliverableAsk slide with funding allocation, milestones, timing, and Series B readiness criteria.
Expected impactMakes the round feel operationally planned instead of generic.
Investor Simulation
i↻ FOLLOW UPThis is an interesting deal with strong clinical validation and a capable team.The traction numbers are impressive for the stage.However, I have concerns about the competitive landscape analysis and whether the team has thought deeply about the EHR platform risk.
The financial projections feel aspirational rather than bottoms-up.I'd want a follow-up meeting to dig into the competitive dynamics and see a more rigorous financial model before bringing this to partners.
When Epic launches their adherence module (and they will), what specifically prevents your hospital customers from switching to the integrated solution they already pay for?
Three things would move this to a "take meeting" verdict: (1) A clear, honest competitive analysis that addresses the EHR risk with data, (2) A bottoms-up financial model showing how you get to $15M ARR, and (3) Evidence that you can sell into new hospital systems without founder-led sales.
Top Strengths
i- Clinical validation data is exceptional — 40% readmission reduction across 3 hospital systems is a strong proof point that few competitors can match
- Founding team has rare combination of deep health tech experience, clinical credibility, and technical AI/ML expertise
- Revenue metrics are strong for the stage — $1.2M ARR with 180% NRR and 15% MoM growth shows product-market fit
- Regulatory strategy is thoughtful — FDA Class II pathway is lower risk than Class III
Priority Fixes
i- 1Rebuild competitive slide with honest positioning and EHR platform risk addressed
- 2Add bottom — up market math to replace generic TAM/SAM/SOM
- 3Break down financial projections into assumption — based model
- 4Create a unit economics slide showing LTV/CAC > 3x
- 5Add a customer case study with quantified outcomes
Investor Readiness
iBlockers
- 1Competitive analysis needs significant strengthening — current version may not survive due diligence
- 2Financial projections lack the rigor expected at Series A
- 3Missing unit economics is a red flag for growth — stage investors
Improvements for Next Level
- →Score 80+ overall with no dimension below 60 for VC-Ready certification
- →Add bottom — up market validation with customer reference calls lined up
- →Prepare a detailed financial model in appendix for data room
Fundraising Readiness Roadmap
Almost Ready for Series ACompetitive analysis needs significant strengthening — current version may not survive due diligence
Financial projections lack the rigor expected at Series A
Missing unit economics is a red flag for growth-stage investors
Address the EHR platform risk head-on — explain why point solution wins
Break down the $15M: "50 hospital systems × $300K ACV"
What Would Change an Investor's Mind
Radar Analysis
iCONTENT / NARRATIVE — SCORE 72 (Grade B)
Benchmark overlay: Sequoia, YC, a16z, HAX
VISUAL ANALYSIS — SCORE 68 (Grade B-)
Benchmark overlay: Sequoia, YC, a16z, HAX
Content & Narrative
i10-dimension analysis
Problem Statement
82Medication non-adherence framed effectively with $528B annual cost statistic. Hospital readmission angle is compelling.
Solution & Value Prop
78Clear product description with AI-driven monitoring. Value proposition is quantified but needs tighter competitive moat articulation.
Market Opportunity
65TAM/SAM/SOM present but top-down analysis feels generic. Missing bottom-up validation.
Business Model
74SaaS pricing is clear with per-bed model. Unit economics are present but CAC payback period is missing.
Traction & Metrics
88Strong traction slide — $1.2M ARR with 180% NRR is excellent. Clinical outcomes data adds credibility.
Competitive Landscape
52Competitive slide is the weakest — 2x2 matrix positions MedSync favorably but feels cherry-picked.
Team & Founders
85Strong founding team with relevant domain expertise. Advisory board adds credibility. Missing key hire plan.
Financial Projections
58Revenue projections are aggressive without clear assumptions. Missing cash flow and burn rate context.
Ask & Use of Funds
67Raising $12M Series A — amount is reasonable but allocation breakdown lacks specificity.
Storytelling & Design
71Clean deck design with good flow. Slides 8-10 are too dense. Needs stronger opening and closing.
Visual & Design
i7-dimension visual pass
Visual Hierarchy
72Good use of headers but some slides have competing focal points
Readability
65Font sizes inconsistent — some body text below 14pt
Layout & Spacing
70Mostly clean layouts but slides 8-10 feel cramped
Consistency
74Color palette is consistent, minor icon style drift
Data Visualization
58Charts lack labels and context — pie chart on slide 7 is unreadable
Credibility Signals
72Good logo placement, but testimonials lack photos
Narrative Flow
66Story arc present but transition from problem to solution is abrupt
Missing Content
i4 itemsKnow Your Business
KYBi- Clear articulation of product architecture and clinical workflow integration
- FDA regulatory pathway well-understood with 510(k) classification
- IP strategy mentioned (3 patents filed)
- Clinical validation data is exceptional — 40% readmission reduction across 3 hospital systems is a strong proof point that few competitors can match
- No discussion of technical debt or scaling challenges
- Manufacturing/deployment complexity not addressed
- Competitive analysis needs significant strengthening — current version may not survive due diligence
- Financial projections lack the rigor expected at Series A
Know Your Customer
KYCi- Strong understanding of hospital administrator pain points (readmission penalties)
- Clinical workflow integration demonstrates deep customer empathy
- Pilot data from 3 hospital systems shows real customer engagement
- Strong traction slide — $1.2M ARR with 180% NRR is excellent. Clinical outcomes data adds credibility.
- No patient perspective — the end user (patient) is absent from the narrative
- Procurement process and buying committee dynamics not discussed
- Competitive analysis needs significant strengthening — current version may not survive due diligence
- Financial projections lack the rigor expected at Series A
Know Your Environment
KYEi- Basic competitive landscape mapping with key players identified
- Market sizing with TAM/SAM/SOM framework
- Competitive slide is the weakest — 2x2 matrix positions MedSync favorably but feels cherry-picked.
- The competitive landscape slide uses a 2x2 matrix with "AI sophistication" vs "Clinical integration" axes. While MedSync sits in the top-right quadrant, this feels self-serving. Competitors like Omnicell, Adherium, and CareSignal are mentioned but their actual strengths are downplayed. No mention of Epic/Cerner building adherence features into their EHR platforms.
- EHR platform risk completely unaddressed
- No regulatory landscape changes analysis beyond CMS penalties
- Missing analysis of international expansion barriers
- No discussion of potential acquirers or exit landscape
Non-Obvious Risk Factors
iBlack Swans
iVC Benchmark Comparison
How your deck compares to top VC-funded startups
Competitive Landscape
iCompetitive Landscape
52/100Competitive slide is the weakest — 2x2 matrix positions MedSync favorably but feels cherry-picked.
- 2x2 competitive matrix present
- Key competitors named
- Matrix axes feel cherry — picked to favor MedSync
- EHR platform risk (Epic/Cerner) not addressed
- No competitive win/loss data
- Competitor strengths are understated
- Address the EHR platform risk head — on — explain why point solution wins
- Add win/loss data: "Won 8 of last 10 competitive evaluations"
- Show a more honest competitive positioning with multiple axes
MedSync positions itself in the AI-powered medication adherence space, competing against point solutions (Omnicell, Adherium, CareSignal), EHR platform features (Epic MyChart, Cerner), and general digital health platforms.The deck's current positioning on "AI sophistication × Clinical integration" works directionally but ignores the platform play risk.
A stronger positioning would emphasize the clinical data flywheel that point solutions and EHR modules can't replicate at speed.
Sector Insights
iHealthTech / Digital Health
Strong HealthTech decks at Series A typically demonstrate regulatory clarity, clinical validation with peer-reviewed or IRB-approved data, and a clear reimbursement strategy.
- Reimbursement strategy — how do hospitals get paid for using MedSync?
- Clinical evidence quality — is the 40% reduction from an RCT or observational study?
- HIPAA compliance and data security architecture details
HealthTech investors increasingly want to see a "regulatory moat" — if you have FDA clearance and competitors don't, that's a 12-18 month head start. Emphasize your regulatory timeline as a competitive advantage, not just a checkbox.
Narrative Review
iThe narrative arc follows a standard Problem → Solution → Traction → Ask structure, which is safe but not memorable.The strongest storytelling moment is the patient story on slide 2, but it's underutilized — it should be the thread that ties the entire deck together.
The transition from Traction (slide 6) to Market (slide 7) is jarring because you go from strong specific data to generic market sizing.Consider flipping the order or using your traction data to anchor the market discussion.The closing needs work — right now it's a standard "pie chart of fund usage" that every VC has seen 1,000 times.
End with vision, not logistics.
Narrative Flow
iCoherence: 68/100Standard linear arc with strong opening momentum that dips in the middle (market & competition) before recovering with team. Needs a stronger emotional close.
Strong emotional opening with patient story
CMS penalty changes create urgency
Transition from problem to solution could be smoother
Great — proof points right after solution
Jarring shift from strong traction to generic market sizing
Weak positioning after strong business model discussion
Strong team slide rebuilds momentum
Functional but not memorable
Investor Questions & Answer Prep
Investor Q&A prep with what each question is really testing.
Epic already has 35% EHR market share. When they add medication adherence to MyChart, why would any hospital pay you $65K/year for a separate tool?
They're probing whether you have a defensible moat beyond being early to market — and whether you understand platform risk.
- Integration depth metrics — how many EHR data points you consume vs. what MyChart exposes
- Switching cost analysis — average implementation time and workflow dependencies hospitals build around your tool
- Feature comparison matrix showing capabilities Epic's roadmap is unlikely to replicate (AI model specificity, pharmacy network integrations)
Acknowledge the platform risk directly — don't dismiss it. Then show evidence of deep integration that would be costly to replicate. Finally, highlight your speed advantage: 2+ years of clinical outcome data that Epic would need to rebuild from scratch.
- x"Epic moves slowly, so we're not worried" — signals naivety about platform competition
- x"We have patents" — without explaining the actual defensibility scope
Your 40% readmission reduction is from 3 pilot hospitals. How do we know this isn't selection bias?
They want to know if your clinical evidence is statistically rigorous or just cherry-picked marketing material.
- Study methodology documentation — patient selection criteria, control groups, statistical significance levels
- Cohort demographics across all 3 hospitals showing diversity in patient population
- Third-party validation — published papers, peer reviews, or independent audits
Acknowledge the sample size limitation honestly. Present the methodology showing it wasn't cherry-picked. Then outline your plan for a larger RCT and timeline to achieve statistically unimpeachable evidence.
- x"40% is so strong it speaks for itself" — shows lack of statistical rigor awareness
- x"All our hospitals showed similar results" — 3 is not a valid sample for generalization claims
Jak policzyliście SOM bottom — up i jaka część rynku jest realnie osiągalna przy obecnych kanałach sprzedaży?
Czy founder rozumie dostępny rynek operacyjnie, a nie tylko cytuje duże liczby z raportów.
- Liczba firm w pierwszym segmencie docelowym
- Zakładany ARPU i realistyczna penetracja w 3 — 5 lat
- Źródła TAM/SAM/SOM z datami
- Beachhead segment i powód wyboru
Zejdź z makro do mikro: liczba klientów x cena x osiągalna penetracja. Pokaż, który segment zdobywasz pierwszy i dlaczego ten kanał ma prawo działać.
- x"Wystarczy 1% ogromnego rynku"
- x"SOM to konserwatywny szacunek" bez metodologii
- x"Rynek rośnie, więc będzie miejsce dla nas"
Jak wygląda 3-letnia projekcja finansowa: MRR/ARR, koszty, burn, runway i moment dojścia do kolejnego kamienia milowego?
Czy founder wie, ile kapitału zużyje i jak zamieni go w mierzalny wzrost wartości spółki.
- Model 36 miesięcy z MRR/ARR, kosztami i burnem
- Najważniejsze założenia: ceny, wolumen sprzedaży, churn, hiring
- Runway po rundzie i data kolejnej decyzji finansowania
- Scenariusz bazowy, konserwatywny i upside
Pokaż liczby jako hipotezy operacyjne. Powiedz, które założenia są najbardziej ryzykowne i jaki eksperyment je zweryfikuje.
- x"Na tym etapie projekcje nie mają sensu"
- x"Będziemy rentowni szybko" bez kosztów
- x"Nie chcemy pokazywać modelu finansowego"
Ile kapitału szukacie, na jakich warunkach i jakie mierzalne kamienie milowe dowieziecie w ciągu 12-18 miesięcy?
Czy runda jest narzędziem do osiągnięcia konkretnego etapu, czy luźną prośbą o finansowanie.
- Kwota rundy i typ instrumentu
- Alokacja środków procentowo i kwotowo
- 3-5 kamieni milowych powiązanych z runwayem
- Obecne zobowiązania, wcześniejsze finansowanie i cash position
Połącz każdą część budżetu z mierzalnym wynikiem. Inwestor ma zobaczyć, co dokładnie kupuje jego kapitał.
- x"Weźmiemy tyle, ile rynek da"
- x"Budżet jest elastyczny"
- x"Najpierw zatrudnimy ludzi, potem doprecyzujemy cele"
Dlaczego MedSync wygra z Omnicell / Adherium, skoro konkurenci mogą dodać podobny workflow do swoich produktów?
Czy przewaga jest defensywna, mierzona i ważna dla klientów, czy tylko opisana jako "lepsze UX" lub "bardziej kompleksowe rozwiązanie".
- Macierz konkurencji z konkretnymi kryteriami
- Dowody, że klienci cenią wskazane przewagi
- Koszty zmiany, dane, integracje, workflow lub inny realny moat
- Win/loss insight z rozmów z klientami
Najpierw uczciwie nazwij mocne strony konkurencji. Potem pokaż jedną lub dwie przewagi, które są ważne, mierzalne i trudne do skopiowania.
- x"Nie mamy bezpośredniej konkurencji"
- x"Jesteśmy tańsi i prostsi"
- x"Konkurenci są starzy" bez dowodu klienta
Kto dokładnie stoi za MedSync i jakie doświadczenie zespołu dowodzi, że potraficie zbudować spółkę w obszarze HealthTech / Digital Health?
Czy inwestor ma komu powierzyć kapitał: kompetencje domenowe, techniczne, sprzedażowe oraz zdolność dowożenia w trudnym, regulowanym rynku.
- Bio founderów z rolami i konkretnymi osiągnięciami
- Doświadczenie w fintech/SaaS/sprzedaży B2B lub windykacji
- Braki w zespole oraz plan zatrudnienia na najbliższe 6-12 miesięcy
- Doradcy, eksperci branżowi lub partnerzy zwiększający wiarygodność
Zacznij od faktów: kto robi produkt, kto sprzedaje, kto zna domenę. Jeśli zespół ma lukę, nazwij ją i pokaż konkretny plan domknięcia, zamiast udawać kompletność.
- x"Zespół pokażemy później"
- x"Mamy dostęp do freelancerów"
- x"AI zrobi większość pracy" bez właściciela technicznego i biznesowego
Jakie twarde dowody pokazują, że klienci faktycznie chcą płacić za MedSync: użytkownicy, pilotaże, LOI, przychody, waitlista albo odzyskane kwoty?
Czy istnieje realny popyt, czy deck opisuje tylko logicznie brzmiący problem bez dowodu kupna.
- Liczba rozmów z klientami i wnioski z nich
- Pilotaże, LOI, waitlista lub pipeline sprzedażowy
- MRR/przychód, jeśli istnieje, albo jasne oznaczenie etapu pre-revenue
- Konkretny dowód bólu klienta: czas, koszt, opóźnione płatności, odzyskane środki
Odpowiedz liczbami, nawet jeśli są wczesne. Jeśli trakcji jeszcze nie ma, pokaż plan walidacji na 30-60 dni i kryteria, po których uznasz, że rynek odpowiada.
- x"Rynek jest ogromny, więc klienci przyjdą"
- x"Jeszcze nie mierzymy trakcji"
- x"Nie mamy danych, ale feedback jest pozytywny" bez przykładów
Czy produkt MedSync już działa i co inwestor może zobaczyć w demo, żeby odróżnić realny software od samej narracji?
Czy ryzyko technologiczne jest ograniczone oraz czy zespół potrafi przełożyć koncepcję na działający workflow.
- Status produktu: koncepcja, prototyp, MVP, beta lub produkcja
- Screenshoty najważniejszych ekranów i demo flow
- Lista funkcji działających dziś vs. roadmapa
- Największe ryzyka techniczne i sposób ich ograniczenia
Nazwij obecny etap bez pudrowania. Pokaż jeden kluczowy workflow end-to-end i powiedz, co jest już zbudowane, co jest makietą, a co wymaga finansowania.
- x"Demo jest poufne"
- x"Produkt jest prawie gotowy" bez dat i zakresu
- x"Najpierw zbierzemy rundę, potem zbudujemy produkt"
Jaki jest konkretny cennik, ARPU, CAC, LTV, marża brutto i payback period, oraz jakie założenia stoją za modelem przychodów?
Czy model biznesowy ma ekonomię venture-scale, czy jest tylko opisem funkcji opakowanych jako SaaS.
- Tabela cenowa i różnice między pakietami
- Założony ARPU, CAC, LTV, churn i payback
- Marża brutto oraz główne koszty obsługi klienta
- Konwersja freemium — > paid, jeśli freemium zostaje w modelu
Podaj model bazowy i zakres wrażliwości. Lepiej pokazać świadome założenia niż udawać, że unit economics są już pewne.
- x"Cennik ustalimy po rundzie"
- x"Freemium samo zbuduje wzrost"
- x"CAC będzie niski, bo produkt jest viralowy" bez mechaniki dystrybucji
Deck vs. Diagnostic
iAI-powered medication adherence platform targeting hospital systems. Clear health tech play with clinical validation, FDA pathway, and per-bed SaaS model.
Slide Impact Matrix
iSlide Heatmap
iMetric Glossary
Plain-English definitions of the main report metrics.
A 0-100 investor-readiness score combining deck content, narrative clarity, visual quality, and fundraising risk signals.
Business Situational Awareness: how clearly the company understands the business, customer, and market environment behind the pitch.
Know Your Business, Know Your Customer, and Know Your Environment. These diagnose business model clarity, customer insight, and market context.
The share of report claims directly supported by content found in the deck. Lower values mean more inference or outside context.
A practical readiness label for the next fundraising conversation, based on blockers, evidence gaps, and stage fit.
The highest-leverage changes to make before the next investor conversation, ordered by likely impact.
A ranked view of where investors are most likely to push back: product, market, traction, competition, timing, team, or unit economics.
A map of slide execution quality versus investor importance. Low-quality, high-importance slides are the urgent fixes.
How smoothly the deck moves from problem to solution, market, traction, business model, team, and ask.
A simplified 2D view of how the startup is positioned against named competitors. AI-researched competitors should be verified.
pitchera.aiScan to view this report on another device
AI-Powered Pitch Deck Analysisv0.17.18
Questions? [email protected]
Like what you see?
Get the same analysis for your pitch deck — from $9 for a Quickscore to $149 for a full VC-Ready Audit.
Analyze My Deck →